Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Small Cell Lung Carcinoma 4Recurrence 4Ovarian Neoplasms 3Lymphoma, Non-Hodgkin 2Triple Negative Breast Neoplasms 1Solid Tumors 1Sarcoma 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Granulocyte Colony-Stimulating Factor 18Surgical Procedures, Operative 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16Specimen Handling 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma × chiauranib × Clear all
NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed
40 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡